Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy

被引:30
作者
Singh, Paras B. [1 ]
Anele, Chukwuemeka [2 ]
Dalton, Emma [2 ]
Barbouti, Omar [2 ]
Stevens, Daniel [3 ]
Gurung, Pratik [1 ]
Arya, Manit [4 ,5 ]
Jameson, Charles [6 ]
Freeman, Alex [6 ]
Emberton, Mark [1 ,4 ]
Ahmed, Hashim U. [1 ,4 ]
机构
[1] UCL, Div Surg & Intervent Sci, London W1P 7NN, England
[2] UCL, Sch Med, London, England
[3] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England
[4] Univ Coll London Hosp, Hosp NHS Fdn Trust, Dept Urol, London, England
[5] Univ London, Barts Canc Inst, London, England
[6] UCL, Hosp NHS Fdn Trust, Dept Histopathol, London, England
关键词
Prostate cancer; Biopsy; Diagnosis; Pathology; Surgery; Therapy; INDEX LESION; MODALITIES; STANDARD; VOLUME; MEN;
D O I
10.1016/j.eururo.2013.09.045
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. Objective: To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. Design, setting, and participants: Our institutional transperineal template prostate-mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identified 291 consecutive men with no prior treatment. Intervention: TTPM biopsies using a 5-mm sampling frame. Outcome measurements and statistical analysis: Suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason <= 3 + 3 and cancer core involvement <= 3 mm. Binary logistic regression modelling was used to determine variables predictive for focal therapy suitability. Results and limitations: The median age was 61 yr, and the median prostate- specific antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores. Of 239 of 291 men with cancer, 29% (70 men), 60% (144 men), and 8% (20 men) had low-, intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation (31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%, 61 men). Binary logistic regression modelling incorporating transrectal biopsy parameters showed no statistically significant predictive variable. When incorporating TTPM parameters, only T stage was a significant negative predictor for suitability (p = 0.001) (odds ratio: 0.001 [95% confidence interval, 0.000-0.048]). Limitations of the study include potential selection bias caused by tertiary referral practise and lack of long-term results on focal therapy efficacy. Conclusions: Focal therapy requires an accurate tool to localise individual cancer lesions. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most of the men were suitable for a tissue preservation strategy. (C) 2013 European Association of Urology. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 30 条
[1]   Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial [J].
Ahmed, H. U. ;
Freeman, A. ;
Kirkham, A. ;
Sahu, M. ;
Scott, R. ;
Allen, C. ;
Van der Meulen, J. ;
Emberton, M. .
JOURNAL OF UROLOGY, 2011, 185 (04) :1246-1254
[2]   Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study [J].
Ahmed, Hashim U. ;
Hindley, Richard G. ;
Dickinson, Louise ;
Freeman, Alex ;
Kirkham, Alex P. ;
Sahu, Mahua ;
Scott, Rebecca ;
Allen, Clare ;
Van der Meulen, Jan ;
Emberton, Mark .
LANCET ONCOLOGY, 2012, 13 (06) :622-632
[3]   Will focal therapy become a standard of care for men with localized prostate cancer? [J].
Ahmed, Hashim Uddin ;
Pendse, Doug ;
Illing, Rowland ;
Allen, Clare ;
van der Meulen, Jan H. P. ;
Emberton, Mark .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (11) :632-642
[4]   Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? [J].
Ahmed, Hashim Uddin ;
Arya, Manit ;
Freeman, Alex ;
Emberton, Mark .
LANCET ONCOLOGY, 2012, 13 (11) :E509-E517
[5]   A biomedical engineering approach to mitigate the errors of prostate biopsy [J].
Ahmed, Hashim Uddin ;
Emberton, Mark ;
Kepner, Gordon ;
Kepner, Jeremy .
NATURE REVIEWS UROLOGY, 2012, 9 (04) :227-U81
[6]   Characterizing Clinically Significant Prostate Cancer Using Template Prostate Mapping Biopsy [J].
Ahmed, Hashim Uddin ;
Hu, Yipeng ;
Carter, Tim ;
Arumainayagam, Nimalan ;
Lecornet, Emilie ;
Freeman, Alex ;
Hawkes, David ;
Barratt, Dean C. ;
Emberton, Mark .
JOURNAL OF UROLOGY, 2011, 186 (02) :458-464
[7]   The Index Lesion and the Origin of Prostate Cancer [J].
Ahmed, Hashim Uddin .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (17) :1704-1706
[8]  
Ahmed HU., An evaluation of lesion control using focal ablation with high intensity focused ultrasound in the treatment of non- metastatic progressive prostate cancer
[9]   Multiparametric MR Imaging for Detection of Clinically Significant Prostate Cancer: A Validation Cohort Study with Transperineal Template Prostate Mapping as the Reference Standard [J].
Arumainayagam, Nimalan ;
Ahmed, Hashim U. ;
Moore, Caroline M. ;
Freeman, Alex ;
Allen, Clare ;
Sohaib, S. Aslam ;
Kirkham, Alex ;
van der Meulen, Jan ;
Emberton, Mark .
RADIOLOGY, 2013, 268 (03) :761-769
[10]   Identifying Candidates for Active Surveillance: An Evaluation of the Repeat Biopsy Strategy for Men with Favorable Risk Prostate Cancer [J].
Barzell, Winston E. ;
Melamed, Myron R. ;
Cathcart, Paul ;
Moore, Caroline M. ;
Ahmed, Hashim U. ;
Emberton, Mark .
JOURNAL OF UROLOGY, 2012, 188 (03) :762-767